{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-013085","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.628652+00:00","generated_at":"2026-05-24T14:53:09.465753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo FY2024 net loss $97.9M; FDA clears ST-503 IND; Fabry BLA path to Accelerated Approval","bullets":["FY2024 net loss $97.9M ($0.49/share) vs $257.8M ($1.48) in 2023; revenue $57.8M vs $176.2M.","Cash $41.9M at Dec 31, 2024; with $10.1M ATM proceeds and $5M Pfizer payment, funds operations into mid-Q2 2025.","FDA cleared IND for ST-503 (chronic neuropathic pain); patient enrollment expected mid-2025; preliminary efficacy data Q4 2026.","FDA agreed to Accelerated Approval for isaralgagene civaparvovec in Fabry using Phase 1/2 data; BLA submission H2 2025.","License agreements with Genentech (Aug 2024) and Astellas (Dec 2024) for STAC-BBB capsid; $20M upfront from Astellas."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-013085","json":"https://secwatch.observer/filing/0001628280-25-013085.json","markdown":"https://secwatch.observer/filing/0001628280-25-013085.md","text":"https://secwatch.observer/filing/0001628280-25-013085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828025013085/0001628280-25-013085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828025013085/sgmo-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:53:09.465753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}